AnaBios Corp
- Headquarters
- SAN DIEGO, X1
- Founded
- 2009
- Latest Form D
- $6.5M, Jun 2022
- Total capital
- $18.1M
- Federal grants
- $4.7M
- 5 awards · 2016–2021
- Private capital raised
- $13.4M
- 4 Form D · last Jun 2022
- 53 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 6 pending · first 2020
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$6.5M
- Federal grantHealth and Human S · Phase II · Development of a novel analgesic for mixed inflammatory and neuropathic pain states$1.7M
- Federal grantHealth and Human S · Phase I · Development of a novel translational pain-drug screening platform for the generation of human-relevant data in preclinical pain drug discovery$320K
- Federal grantHealth and Human S · Phase II · Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment$1.1M
- Private capital raisedForm D · SEC · 3rd filing$961K
- Federal grantHealth and Human S · Phase II · Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds$550K
- Federal grantHealth and Human S · Phase II · Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds$945K
- Private capital raisedForm D · SEC · 2nd filing$5.1M
- Private capital raisedForm D · SEC · 1st filing$800K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
Researcher links verified by same-company patents and grants- Andrea P. GhettiResearcherExecutive OfficerLinked by 1 patent · $3.5M in grants as PI
- Andre GhettiExecutive OfficerNamed in SEC Form D filings
- George E GoldsmithExecutive OfficerNamed in SEC Form D filings
- Ian WisenbergExecutive OfficerNamed in SEC Form D filings
- Jack ReynoldsExecutive Officer, DirectorNamed in SEC Form D filings
- Martin E WatersExecutive OfficerNamed in SEC Form D filings
Show all 10 people
- Paul MillerExecutive OfficerNamed in SEC Form D filings
- Peter E CrowleyExecutive Officer, DirectorNamed in SEC Form D filings
- Richard E ErdmanDirectorNamed in SEC Form D filings
- Stephen F. FlaimDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 8- GrantedMethod For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsUSPTOUS 10,955,409
- GrantedSystem and Methods for Predicting Drug-Induced Inotropic and Pro-Arrhythmia RiskUSPTOUS 10,794,897
- PendingMethod For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsUSPTOApplication PCTUS2018028421
Show all 8 patent records
- Method For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsMar 23, 2021 · US 10,955,409Granted
- System and Methods for Predicting Drug-Induced Inotropic and Pro-Arrhythmia RiskOct 6, 2020 · US 10,794,897Granted
- Method For The Identification Of Sensory Neuron Subtypes In Ex Vivo PreparationsApplication PCTUS2018028421Pending
- System And Methods For Predicting Drug-induced Inotropic And Pro-arrhythmia RiskApplication PCTUS2018016504Pending
- Method for The Identification of Sensory Neuron Subtypes in Ex Vivo PreparationsApplication 62488667Pending
- Therapeutic Uses Of Cardiac Myosin InhibitorsApplication PCTUS2023031932Pending
- System and Methods for Predicting Drug-Induced Inotropic and Pro-Arrhythmia RiskApplication 62454786Pending
- Therapeutic Uses Of Cardiac Myosin InhibitorsApplication 63403547Pending
Recent research by its founders
- A Comprehensive Metric for ‘Spike’ Related Effects in Single Chalcogenide Xpoint Memory20260 cites
- Microscopic model of the operation of the Single-chalcogenide X-point Memory20250 cites
- VT Window Model of the Single-Chalcogenide Xpoint Memory (SXM)20246 cites
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .